Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Last Close
Feb 06  •  04:00PM ET
74.92
Dollar change
+1.71
Percentage change
2.34
%
Index- P/E- EPS (ttm)-3.65 Insider Own2.25% Shs Outstand70.64M Perf Week-15.30%
Market Cap5.29B Forward P/E- EPS next Y-1.38 Insider Trans0.00% Shs Float69.05M Perf Month13.09%
Enterprise Value4.50B PEG- EPS next Q-0.37 Inst Own98.46% Short Float9.05% Perf Quarter132.60%
Income-210.92M P/S- EPS this Y-74.45% Inst Trans-1.24% Short Ratio3.84 Perf Half Y362.47%
Sales0.00M P/B5.90 EPS next Y-1.27% ROA-23.90% Short Interest6.25M Perf YTD7.72%
Book/sh12.69 P/C6.62 EPS next 5Y- ROE-25.31% 52W High94.90 -21.05% Perf Year144.04%
Cash/sh11.31 P/FCF- EPS past 3/5Y-24.81% -51.75% ROIC-27.24% 52W Low13.22 466.72% Perf 3Y-
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility7.46% 6.43% Perf 5Y-
Dividend TTM- EV/Sales- EPS Y/Y TTM-64.91% Oper. Margin- ATR (14)5.14 Perf 10Y-
Dividend Ex-Date- Quick Ratio14.15 Sales Y/Y TTM- Profit Margin- RSI (14)44.65 Recom1.00
Dividend Gr. 3/5Y- - Current Ratio14.15 EPS Q/Q-87.88% SMA20-11.21% Beta-1.87 Target Price107.80
Payout- Debt/Eq0.01 Sales Q/Q- SMA509.65% Rel Volume0.68 Prev Close73.21
Employees163 LT Debt/Eq0.01 EarningsNov 06 AMC SMA200113.97% Avg Volume1.63M Price74.92
IPOFeb 03, 2023 Option/ShortYes / Yes EPS/Sales Surpr.0.27% - Trades Volume1,101,470 Change2.34%
Date Action Analyst Rating Change Price Target Change
May-02-25Initiated Citigroup Buy $60
Feb-28-25Initiated William Blair Outperform
Jan-08-25Initiated Stifel Buy $50
Dec-04-24Initiated H.C. Wainwright Buy $80
Sep-23-24Initiated Morgan Stanley Overweight $118
May-21-24Initiated JP Morgan Overweight $65
Apr-09-24Initiated Cantor Fitzgerald Overweight $65
Oct-19-23Initiated JMP Securities Mkt Outperform $90
Jul-27-23Initiated Piper Sandler Overweight $58
May-25-23Resumed Jefferies Buy $34 → $41
Feb-04-26 09:30AM
Jan-23-26 09:18AM
Jan-16-26 12:13PM
10:47AM
Jan-15-26 11:35AM
11:07AM Loading…
11:07AM
10:17AM
Jan-12-26 12:00PM
Jan-11-26 04:05PM
Jan-09-26 11:19AM
09:58AM
Jan-08-26 09:12AM
Jan-05-26 10:37AM
Dec-24-25 10:49AM
Dec-23-25 10:46AM
10:11AM Loading…
Dec-22-25 10:11AM
Dec-17-25 08:30AM
Dec-15-25 10:32AM
Dec-12-25 10:37AM
Dec-11-25 04:28PM
04:01PM
10:23AM
08:10AM
Dec-10-25 10:17AM
Dec-09-25 11:15PM
02:23PM
11:15AM
09:27AM
Dec-08-25 08:15PM
04:15PM
04:01PM Loading…
04:01PM
12:46PM
10:36AM
09:12AM
08:00AM
05:32AM
Dec-07-25 06:20PM
Nov-16-25 10:14PM
Nov-06-25 04:01PM
Oct-30-25 02:11PM
Oct-24-25 11:39AM
Sep-21-25 09:23AM
Sep-12-25 08:15AM
Sep-02-25 08:30AM
Aug-19-25 04:05PM
Aug-11-25 08:22PM
Aug-07-25 04:20PM
09:55AM
09:01AM
Aug-06-25 04:01PM
Jun-24-25 05:42PM
Jun-20-25 07:30PM
May-29-25 04:05PM
May-08-25 04:05PM
Apr-25-25 04:31PM
Apr-21-25 08:37AM
Apr-18-25 11:25AM
10:26AM
Apr-15-25 10:35AM
10:00AM
Apr-14-25 11:12AM
Mar-24-25 07:21PM
Mar-20-25 09:28AM
Mar-03-25 04:20PM
Feb-27-25 04:05PM
Feb-14-25 07:56AM
Jan-30-25 08:30AM
Dec-18-24 10:25AM
Dec-17-24 04:01PM
Dec-16-24 01:33PM
Dec-08-24 06:05AM
Nov-27-24 10:15AM
Nov-22-24 07:45AM
Nov-15-24 08:30AM
Nov-13-24 04:05PM
04:01PM
Oct-31-24 08:30AM
Oct-24-24 07:58PM
Oct-16-24 08:45AM
Oct-09-24 09:55AM
Oct-04-24 08:00AM
Sep-29-24 02:05AM
Sep-20-24 01:17PM
Sep-17-24 04:05PM
Sep-05-24 01:07AM
Sep-02-24 06:05PM
Aug-27-24 04:05PM
Aug-26-24 04:05PM
Aug-13-24 02:00PM
Aug-12-24 04:08PM
Aug-08-24 08:18PM
04:05PM
Jul-30-24 03:07PM
Jul-24-24 08:55AM
Jul-17-24 10:47AM
Jul-12-24 06:08AM
Jun-28-24 10:09AM
Jun-17-24 09:53AM
Jun-11-24 07:31PM
09:59AM
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its pipeline includes Aleniglipron GSBR-1290, ACCG-2671, GIPR, GCGR, ANPA-0073, and LTSE-2578. The company was founded by Raymond C. Stevens in 2016 and is headquartered in South San Francisco, CA.
Last Close
Feb 06  •  04:00PM ET
216.61
Dollar change
+0.86
Percentage change
0.40
%
DHR Danaher Corp daily Stock Chart
IndexS&P 500 P/E42.91 EPS (ttm)5.05 Insider Own8.88% Shs Outstand706.90M Perf Week-1.04%
Market Cap153.00B Forward P/E23.77 EPS next Y9.11 Insider Trans-1.76% Shs Float643.61M Perf Month-8.05%
Enterprise Value166.81B PEG2.74 EPS next Q1.94 Inst Own82.63% Short Float1.19% Perf Quarter2.07%
Income3.61B P/S6.23 EPS this Y7.87% Inst Trans-0.29% Short Ratio2.09 Perf Half Y9.13%
Sales24.57B P/B2.91 EPS next Y8.31% ROA4.47% Short Interest7.66M Perf YTD-5.38%
Book/sh74.32 P/C33.15 EPS next 5Y8.66% ROE7.05% 52W High242.80 -10.79% Perf Year2.11%
Cash/sh6.53 P/FCF29.17 EPS past 3/5Y-19.38% 0.67% ROIC5.09% 52W Low171.00 26.67% Perf 3Y-8.65%
Dividend Est.1.32 (0.61%) EV/EBITDA21.71 Sales past 3/5Y-2.67% 1.97% Gross Margin68.77% Volatility2.79% 2.64% Perf 5Y1.08%
Dividend TTM1.28 (0.59%) EV/Sales6.79 EPS Y/Y TTM-4.81% Oper. Margin21.32% ATR (14)5.66 Perf 10Y272.10%
Dividend Ex-DateDec 26, 2025 Quick Ratio1.51 Sales Y/Y TTM2.90% Profit Margin14.71% RSI (14)37.35 Recom1.39
Dividend Gr. 3/5Y8.58% 12.20% Current Ratio1.87 EPS Q/Q12.65% SMA20-5.94% Beta0.93 Target Price264.18
Payout25.35% Debt/Eq0.35 Sales Q/Q4.59% SMA50-5.57% Rel Volume1.18 Prev Close215.75
Employees63000 LT Debt/Eq0.35 EarningsJan 28 BMO SMA2003.72% Avg Volume3.66M Price216.61
IPODec 10, 1969 Option/ShortYes / Yes EPS/Sales Surpr.3.11% 0.40% Trades Volume4,310,975 Change0.40%
Date Action Analyst Rating Change Price Target Change
Dec-09-25Initiated Goldman Buy $265
Dec-02-25Initiated Morgan Stanley Overweight $270
Oct-08-25Downgrade Rothschild & Co Redburn Buy → Neutral $220
Jul-11-25Upgrade Scotiabank Sector Perform → Sector Outperform $275
Apr-10-25Upgrade Barclays Equal Weight → Overweight $205
Mar-21-25Upgrade Goldman Neutral → Buy $260
Mar-14-25Upgrade Stifel Hold → Buy $260
Feb-03-25Downgrade Raymond James Outperform → Mkt Perform
Dec-23-24Initiated Scotiabank Sector Perform
Dec-19-24Initiated Guggenheim Buy $275
Feb-05-26 03:00AM
Feb-04-26 04:00PM
12:41AM
Feb-02-26 10:28AM
Jan-29-26 12:31AM
04:32PM Loading…
Jan-28-26 04:32PM
02:02PM
01:22PM
01:01PM
11:15AM
10:55AM
10:09AM
09:46AM
09:30AM
07:10AM
06:42AM Loading…
06:42AM
06:19AM
06:17AM
06:00AM
Jan-26-26 10:07PM
09:33PM
10:00AM
08:20AM
Jan-25-26 07:52AM
Jan-23-26 04:20PM
09:15AM
08:48AM
07:17AM
Jan-21-26 10:00AM
Jan-20-26 11:06PM
11:02PM Loading…
Jan-19-26 11:02PM
07:37AM
Jan-18-26 10:35PM
12:54AM
Jan-15-26 05:51AM
Jan-14-26 01:44PM
07:57AM
Jan-13-26 04:32PM
Jan-12-26 03:58PM
09:00AM
Jan-08-26 08:00AM
Jan-07-26 06:21AM
Jan-05-26 04:15PM
Dec-31-25 10:08AM
Dec-24-25 11:48AM
Dec-23-25 11:40AM
Dec-21-25 09:44AM
Dec-18-25 09:55AM
Dec-17-25 07:30AM
Dec-16-25 07:36AM
Dec-15-25 06:30AM
Dec-09-25 04:15PM
08:16AM
Dec-05-25 06:09AM
Dec-04-25 01:59PM
01:53PM
12:05AM
Nov-28-25 06:34PM
Nov-26-25 04:58PM
11:30AM
07:48AM
Nov-25-25 01:03PM
Nov-20-25 11:30AM
Nov-12-25 09:45PM
11:40AM
10:00AM
Nov-11-25 04:15PM
Nov-10-25 11:40AM
Nov-04-25 04:26AM
Oct-30-25 11:41AM
Oct-28-25 01:34AM
Oct-27-25 09:15AM
Oct-24-25 11:52AM
09:30AM
Oct-23-25 09:20AM
Oct-22-25 02:48PM
09:21AM
07:29AM
Oct-21-25 05:08PM
04:05PM
03:00PM
02:17PM
02:12PM
01:41PM
01:35PM
12:40PM
11:42AM
09:42AM
09:30AM
07:15AM
06:44AM
06:23AM
06:17AM
06:09AM
06:00AM
Oct-20-25 11:40AM
Oct-19-25 11:04PM
07:33AM
Oct-17-25 10:18AM
Oct-16-25 04:35PM
Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, and Diagnostics. The Biotechnology segment includes bioprocessing, discovery, and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RALES MITCHELL PChairman of Exec. CommitteeNov 25 '25Sale230.3840,6259,359,067850,000Nov 26 04:30 PM
The Mitchell P. Rales Family TSee RemarksNov 25 '25Proposed Sale226.9840,6259,221,063Nov 25 05:23 PM
Glenstone FoundationSee RemarksNov 25 '25Proposed Sale226.98146,95733,356,300Nov 25 05:22 PM
List TeriDirectorNov 18 '25Option Exercise71.883,298237,06024,060Nov 19 05:00 PM
List TeriDirectorNov 18 '25Sale226.503,298746,99720,762Nov 19 05:00 PM
List TeriDirectorNov 18 '25Proposed Sale226.503,298746,997Nov 18 03:32 PM
McGrew MatthewEVP & Chief Financial OfficerNov 11 '25Option Exercise62.8516,1721,016,41036,234Nov 13 05:00 PM
McGrew MatthewEVP & Chief Financial OfficerNov 11 '25Sale214.6216,1723,470,83120,062Nov 13 05:00 PM
Ellis Brian WSenior Vice President - GCNov 12 '25Option Exercise58.5921,7761,275,85629,220Nov 13 05:00 PM
Ellis Brian WSenior Vice President - GCNov 12 '25Sale219.2321,7764,773,86314,553Nov 13 05:00 PM
RALES MITCHELL PChairman of Exec. CommitteeNov 12 '25Sale218.69437,00095,566,167553,228Nov 13 04:30 PM
Couchara GeorgeannSVP, Human ResourcesNov 10 '25Option Exercise88.244,176368,4907,799Nov 12 05:00 PM
Couchara GeorgeannSVP, Human ResourcesNov 10 '25Sale210.425,1741,088,7042,625Nov 12 05:00 PM
Mitchell P. RalesDir; Chmn. of Exec. Comm.Nov 12 '25Proposed Sale209.94437,00091,743,780Nov 12 04:30 PM
Ellis Brian WOfficerNov 12 '25Proposed Sale219.2321,7764,773,864Nov 12 02:35 PM
McGrew MatthewOfficerNov 11 '25Proposed Sale214.6216,1723,470,831Nov 12 08:56 AM
Couchara GeorgeannOfficerNov 10 '25Proposed Sale210.425,1741,088,704Nov 10 02:46 PM
RALES MITCHELL PChairman of Exec. CommitteeOct 31 '25Sale216.06600,000129,636,027990,228Nov 04 04:30 PM
Mitchell P. RalesDir; Chmn. of Exec. Comm.Oct 31 '25Proposed Sale214.01600,000128,406,000Oct 31 06:38 PM
List TeriDirectorAug 22 '25Sale211.062,778586,31920,751Aug 25 05:00 PM
List TeriDirectorAug 22 '25Proposed Sale211.062,778586,320Aug 22 12:18 PM
LOHR WALTER GFormer DirectorJul 22 '25Proposed Sale188.152,719511,588Jul 22 11:49 AM
Zerhouni Elias A.DirectorJul 15 '25Option Exercise59.343,928233,08842,014Jul 16 05:01 PM
SCHWIETERS JOHN TDirectorJul 15 '25Option Exercise59.343,928233,08821,024Jul 16 05:01 PM
List TeriDirectorJul 02 '25Option Exercise59.343,928233,08824,667Jul 07 05:00 PM
RALES STEVEN MChairmanMay 12 '25Sale196.741,250,000245,919,3913,105,808May 14 05:19 PM
RALES STEVEN MOfficerMay 12 '25Proposed Sale194.821,250,000243,525,000May 12 09:30 PM
Raskas DanielFormer OfficerMay 02 '25Proposed Sale201.037,0531,417,865May 02 10:45 AM
Riley Christopher PaulExecutive Vice PresidentApr 30 '25Option Exercise76.477,801596,54230,984May 01 05:01 PM
Riley Christopher PaulExecutive Vice PresidentApr 30 '25Sale198.0015,8053,129,42415,179May 01 05:01 PM
Riley Christopher PaulOfficerApr 30 '25Proposed Sale198.0015,8053,129,421Apr 30 03:41 PM
Glenstone FoundationSee RemarksApr 24 '25Proposed Sale196.50598,281117,562,216Apr 24 05:28 PM
King WilliamFormer OfficerMar 11 '25Proposed Sale207.1464,69713,401,340Mar 11 04:03 PM
King WilliamOfficerFeb 21 '25Proposed Sale209.97114,35124,010,531Feb 21 04:18 PM
Sabeti Pardis Cformer Board of DirectorsFeb 18 '25Proposed Sale204.284,337885,953Feb 18 01:04 PM